The role of rituximab maintenance in elderly patients with mantle cell lymphoma in first remission - single centre experience

Abstract

Mantle cell lymphoma (MCL) is a rare and prognostically unfavourable malignancy. CD20 antigen expression on the surface of lymphoma cells enables the potential addition of anti-CD20 immunotherapy to therapeutic regimens in order to improve treatment outcome.

Keywords

• lymphoma
• immunotherapy
• maintenance treatment
• rituximab